Biotech Sector Considers New Funding Vehicle: FDA Priority Review Voucher
This article was originally published in The Pink Sheet Daily
Executive Summary
Big Pharma execs say vouchers may be worth $100 million to $200 million. Two small-cap biotechs among those hoping to cash in.
You may also be interested in...
Priority Review Voucher Program Relies On Perceptions, BVGH Head Warns
Coartem may not be perfect test case for advocates of incentive program.
Priority Review Voucher Program Relies On Perceptions, BVGH Head Warns
Coartem may not be perfect test case for advocates of incentive program.
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies